The 340B-program landscape has changed dramatically. For the 340B program’s first 28 years after its 1992 inception, the basic list of Best Practices for eligible entities remained largely unchanged — aside from the dramatically-increased importance of using specialized software. But since the June, 2020 introduction of 340B ESP — which has led to an avalanche … Read More
340B ESP and drug manufacturer restrictions are only part of the reason As we noted in a previous post, for 340B-eligible hospitals dealing with increasingly squeezed bottom lines, an in-house specialty pharmacy offers enormous savings and revenue potential. Some covered entities generate as much as 600% in specialty pharmacy revenue from 340B drugs as they … Read More
Introducing ProxsysRx’s 340B Program ROI Calculator The 340B program has often been described, and with good reason, as a black box. There are dozens of factors impacting an individual hospital’s relative success or failure in generating positive returns from a program. ProxsysRx has optimized dozens of 340B programs — generating tens of millions in savings … Read More
For 340B-eligible hospitals dealing with increasingly tight bottom lines (which essentially means all 340B-eligible hospitals), an in-house specialty pharmacy offers enormous savings and revenue potential. Some covered entities generate as much as 600% in specialty pharmacy revenue from 340B drugs as they do in traditional retail / outpatient or contract pharmacy 340B revenue. What is … Read More
Getting started with the 340b program If your hospital isn’t already 340B registered and eligible, you might want to refer to our previous blog post, Are you ready to enroll in the 340B program? What is a Specialty Pharmacy? The National Association of Specialty Pharmacy defines a specialty pharmacy as a state-licensed pharmacy that solely … Read More
